TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16683415

Group type: EXPERIMENTAL
Intervention: Limited resections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Curative radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypofractionated stereotactic body radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant platinum-based chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 0
Study: 14688709

Group type: EXPERIMENTAL
Intervention: Initial resection for clinically unsuspected N2 nodal disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: No initial resection after neoadjuvant therapy for N2 nodal disease
Number of subjects: 0
Study: 12097595

Group type: EXPERIMENTAL
Intervention: HPV virus-like particle (VLP) vaccine administered intramuscularly at months 0, 2, 6, and a fourth dose at month 12 for half of the participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV virus-like particle (VLP) vaccine
Number of subjects: 0
Study: 9814730

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 800 microg once daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 400 microg twice daily
Number of subjects: 36
Study: 8029608

Group type: EXPERIMENTAL
Intervention: Dipyrone and hydrocortisone
Number of subjects: 116

Group type: COMPARATOR
Intervention: Hydrocortisone only
Number of subjects: 116

Group type: COMPARATOR
Intervention: Dipyrone only
Number of subjects: 116

Group type: COMPARATOR
Intervention: Hydration only
Number of subjects: 116

Group type: COMPARATOR
Intervention: DW 50% only
Number of subjects: 116
Study: 2741711

Group type: EXPERIMENTAL
Intervention: Prior sleep
Number of subjects: 24

Group type: COMPARATOR
Intervention: Awake control group
Number of subjects: 24
Study: 31509228

Group type: EXPERIMENTAL
Intervention: Psoriasis lesions
Number of subjects: 10
Study: 27637737

Group type: EXPERIMENTAL
Intervention: Overdentures supported and retained by cantilevered bars on two canine implants (Group I)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Overdentures retained by straight bars on two canine implants and supported by two-first molar implants (Group II)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group II
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 25043606

Group type: EXPERIMENTAL
Intervention: CRP genetic variants (rs1205, rs1800947, rs1130864, rs2808630, rs3093077)
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: CRP allele score as instrumental variable
Number of subjects: 727
Study: 24284154

Group type: EXPERIMENTAL
Intervention: Preoperative Radiation Therapy (RT)
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Postoperative Radiation Therapy (RT)
Number of subjects: 1015

Group type: COMPARATOR
Intervention: No Radiation Therapy (RT)
Number of subjects: 1015
Study: 22269199

Group type: EXPERIMENTAL
Intervention: High-speed bur for amalgam restorations (Group 1, n=9)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Ultrasonic tip for amalgam restorations (Group 2, n=10)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High-speed bur for composite resin restorations (Group 3, n=8)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Ultrasonic tip for composite resin restorations (Group 4, n=10)
Number of subjects: 37

Group type: COMPARATOR
Intervention: High-speed bur (for both materials)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Ultrasonic diamond tip (for both materials)
Number of subjects: 37
Study: 19959686

Group type: EXPERIMENTAL
Intervention: OGG1 (S326C) polymorphism in current and former cigarette smokers
Number of subjects: 1604

Group type: EXPERIMENTAL
Intervention: XRCC1 R194W polymorphism in regular cigarette smokers
Number of subjects: 1604
Study: 16903842

Group type: EXPERIMENTAL
Intervention: Resistive heating (group 1)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Passive warming (group 2)
Number of subjects: 19
Study: 15128017

Group type: EXPERIMENTAL
Intervention: Plasmat Futura system
Number of subjects: 21

Group type: COMPARATOR
Intervention: Plasmat Secura system
Number of subjects: 21
Study: 11358648

Group type: EXPERIMENTAL
Intervention: Estradiol valerate (2 mg/day)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Estradiol valerate (2 mg/day) + Dienogest (2 mg/day)
Number of subjects: 52
Study: 9000164

Group type: EXPERIMENTAL
Intervention: 0.45% saline oral ingestion (ORAL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.45% saline infusion (i.v.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No fluid (NF)
Number of subjects: 8
Study: 8173763

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 3630587

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 0
Study: 31343548

Group type: EXPERIMENTAL
Intervention: Beetroot Juice (BEET) 400-mg nitrate
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Citrulline Malate (CitMal) 8 g
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 27
Study: 27853809

Group type: EXPERIMENTAL
Intervention: Ciraparantag (100 to 300 mg IV)
Number of subjects: 80
Study: 26033407

Group type: EXPERIMENTAL
Intervention: Moderately aerobic training (60-min sessions, 3-5 times a week for 6 months)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sedentary lifestyle (no exercise training)
Number of subjects: 36
Study: 23553596

Group type: EXPERIMENTAL
Intervention: deferasirox 5 mg/kg/day
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: deferasirox 10 mg/kg/day
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: deferasirox 20 mg/kg/day (dose-escalated from 10 mg/kg/day at Week 24)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: deferasirox >12.5-≤17.5 mg/kg/day
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: deferasirox dosing strategies
Number of subjects: 166
Study: 21464362

Group type: EXPERIMENTAL
Intervention: CALM (cognitive behavior therapy and pharmacotherapy recommendations)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: UC (usual care)
Number of subjects: 1004
Study: 19100611

Group type: EXPERIMENTAL
Intervention: Self-adhesive resin cement (RelyX Unicem Aplicap, 3M ESPE, Germany)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Zinc phosphate cement (Richter & Hoffmann, Berlin, Germany)
Number of subjects: 49
Study: 16688562

Group type: EXPERIMENTAL
Intervention: Process Oriented Memory Training (POT) group (n=24)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Strategy Training (ST) group (n=22)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Low Dose Memory Training Control group (n=16)
Number of subjects: 62
Study: 14687320

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 752

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 752
Study: 11769634

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg once a day
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 9263380

Group type: EXPERIMENTAL
Intervention: Sirolimus 3 mg/m2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sirolimus 5 mg/m2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sirolimus 10 mg/m2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sirolimus 15 mg/m2
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8513962

Group type: EXPERIMENTAL
Intervention: Goserelin depot (n = 29)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Low-dose cyclic oral contraceptive (n = 28)
Number of subjects: 57
Study: 3799579

Group type: COMPARATOR
Intervention: Prednisone alone (Treatment A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prednisone with sucralfate (Treatment B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prednisone with sucralfate administered 2 h after (Treatment C)
Number of subjects: 12
Study: 29303467

Group type: EXPERIMENTAL
Intervention: Kineflex|C cervical artificial disc (TDR)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 269
Study: 26956654

Group type: EXPERIMENTAL
Intervention: Mindfulness strategies
Number of subjects: 7

Group type: COMPARATOR
Intervention: Avoidance strategies
Number of subjects: 7
Study: 25763936

Group type: EXPERIMENTAL
Intervention: Behavioral weight reduction program for 3 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study: 24163147

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) for dabigatran vs warfarin
Number of subjects: 35
Study: 20883736

Group type: EXPERIMENTAL
Intervention: PCV7+MnCC vaccine
Number of subjects: 711

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 711

Group type: COMPARATOR
Intervention: MnCC vaccine
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: All vaccine groups
Number of subjects: 711
Study: 17690599

Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release 9 mg/day
Number of subjects: 36
Study: 15118754

Group type: EXPERIMENTAL
Intervention: High-intensity intervention (CHWs with cleaning equipment and 5-9 visits over a year)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Low-intensity intervention (CHWs with bedding encasements and fewer visits)
Number of subjects: 274
Study: 11851734

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injections
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no BTX‐A injections)
Number of subjects: 12
Study: 9745864

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 30 U/m2 per week
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no rhGH for the first year)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 90
Study: 7803226

Group type: EXPERIMENTAL
Intervention: Hypnotic suggestions to increase cutaneous blood flow
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hypnotic suggestions to decrease cutaneous blood flow
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 3182477

Group type: EXPERIMENTAL
Intervention: Methylcholine (MCh) 5 x 10(-3) M injected after 1 hour of exercise in heat
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Methylcholine (MCh) 5 x 10(-3) M
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Methylcholine (MCh) 5 x 10(-4) M and above
Number of subjects: 15
Study: 30420092

Group type: EXPERIMENTAL
Intervention: Progressive autonomy in surgical training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Constant supervision in surgical training
Number of subjects: 0
Study: 30200394

Group type: EXPERIMENTAL
Intervention: ORS⁺Lr&amp;Z (Oral Rehydration Solution enriched with Lactobacillus reuteri DSM 17938 and zinc)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard ORS (ORS-Lr&amp;Z)
Number of subjects: 51
Study: 27232649

Group type: EXPERIMENTAL
Intervention: Oral betrixaban (80 mg once daily for 35 to 42 days)
Number of subjects: 7513

Group type: COMPARATOR
Intervention: Subcutaneous enoxaparin (40 mg once daily for 10±4 days)
Number of subjects: 7513
Study: 25306266

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (300 g/d)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional yogurt (300 g/d)
Number of subjects: 72
Study: 22574586

Group type: EXPERIMENTAL
Intervention: Qingchang Huashi Recipe (QHR) and Guanchang Recipe (GR) in the active stage, Fuzheng Qingchang Recipe in the remission stage
Number of subjects: 53

Group type: COMPARATOR
Intervention: Mesalazine enteric coated tablet (MSRT, 1.0 g, 4 times daily) in the active stage, MSRT (0.5 g, three times daily) in the remission stage
Number of subjects: 53
Study: 20099988

Group type: EXPERIMENTAL
Intervention: Telavancin 10 mg/kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17567399

Group type: EXPERIMENTAL
Intervention: Oxford House recovery home
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual after-care condition
Number of subjects: 150
Study: 16623675

Group type: EXPERIMENTAL
Intervention: FX60S dialyzer
Number of subjects: 9

Group type: COMPARATOR
Intervention: F60S dialyzer
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: FX60S and F60S dialyzers
Number of subjects: 9
Study: 12623762

Group type: EXPERIMENTAL
Intervention: Troleandomycin (TAO) 500 mg daily for 2 days before omeprazole (OP) administration
Number of subjects: 18

Group type: COMPARATOR
Intervention: Omeprazole (OP) alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Troleandomycin (TAO)
Number of subjects: 18
Study: 10556441

Group type: EXPERIMENTAL
Intervention: Simulator practice (Group A)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No practice (Group B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study: 8744579

Group type: EXPERIMENTAL
Intervention: Env 2‐3 in MTP‐PE/MF59
Number of subjects: 78

Group type: COMPARATOR
Intervention: Env 2‐3 in MF59 without MTP‐PE
Number of subjects: 78
Study: 1650685

Group type: EXPERIMENTAL
Intervention: Transcatheter hepatic arterial chemo-embolizations with MMC 20 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Transcatheter hepatic arterial chemo-embolizations with MMC 20 mg plus lipiodol 10 ml
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Transcatheter hepatic arterial chemo-embolizations with MMC 20 mg plus MTXmc 150 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Direct puncture of the main trunk of the portal vein to infuse 500 mg of 5-FU during operation
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Injection of MMC 20 mg through a catheter inserted into the hepatic artery 4 weeks after operation
Number of subjects: 26
Study: 6131800

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (40 mg in 5 ml i.m. three times daily for 6 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (5 ml in normal saline i.m. three times daily for 6 days)
Number of subjects: 32
Study: 31476429

Group type: EXPERIMENTAL
Intervention: Alprazolam (GABAA agonist)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Baclofen (GABAB agonist)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 26013322

Group type: EXPERIMENTAL
Intervention: Placebo treatment (hypertonic saline with lidocaine)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Open treatment (hypertonic saline with lidocaine)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Hidden treatment (hypertonic saline with lidocaine)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (matching placebo)
Number of subjects: 48
Study: 24755125

Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride modified release capsules (0.4 mg) alone and with mirabegron (100 mg once daily)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mirabegron alone and with tamsulosin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Co-treatment of mirabegron and tamsulosin
Number of subjects: 48
Study: 22735041

Group type: EXPERIMENTAL
Intervention: NOURISH intervention (n=46)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (n=50)
Number of subjects: 96
Study: 19542666

Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiotherapy (IMRT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Three-Dimensional Conformal Radiotherapy (3D CRT)
Number of subjects: 20
Study: 18086052

Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite (CaHA) gel
Number of subjects: 205

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 205
Study: 15331687

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 24
Study: 12577350

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Xueshuantong (XST)
Number of subjects: 57
Study: 10225504

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Exposure therapy
Number of subjects: 12
Study: 8547197

Group type: EXPERIMENTAL
Intervention: Follow-up by general practitioners (GP)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Usual practice follow-up in hospital clinics
Number of subjects: 296
Study: 2147702

Group type: EXPERIMENTAL
Intervention: Outpatient group behavioral therapy including aerobic exercise (BE)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Behavioral therapy only (B)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Aerobic exercise only (E)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Waiting-list control (WL)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: All treatment groups (BE, B, E)
Number of subjects: 96
Study: 6986967

Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (IF-RT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: CNS prophylaxis (cranial irradiation and intrathecal methotrexate)
Number of subjects: 69

Group type: COMPARATOR
Intervention: No CNS prophylaxis
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Oral mercaptopurine and methotrexate for 18 months (for all children)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Stages I-II
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Stages III-IV
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: IF-RT in Stages III-IV
Number of subjects: 69
Study: 31628035

Group type: EXPERIMENTAL
Intervention: GnRH agonist luteal support (0.1 mg subcutaneously every other day, starting on day 3 after embryo transfer)
Number of subjects: 39

Group type: COMPARATOR
Intervention: HCG luteal support (80 µg on day 3 after embryo transfer)
Number of subjects: 39
Study: 28581821

Group type: EXPERIMENTAL
Intervention: Technology-assisted case management (TACM)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 113
Study: 26181634

Group type: EXPERIMENTAL
Intervention: High-volume aerobic exercise (300 min/wk)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Moderate-volume aerobic exercise (150 min/wk)
Number of subjects: 400
Study: 24141239

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 21111377

Group type: EXPERIMENTAL
Intervention: Acuvue® Oasys™ with Hydraclear® Plus (senofilcon A) silicone hydrogel contact lenses, replaced every 2 weeks
Number of subjects: 0
Study: 18540369

Group type: EXPERIMENTAL
Intervention: Combination therapy with methylprednisolone (mPSL) and high-dose immunoglobulin (IVIg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-combination therapy (IVIg alone)
Number of subjects: 0
Study: 16509915

Group type: EXPERIMENTAL
Intervention: Visible respiratory function monitor
Number of subjects: 35

Group type: COMPARATOR
Intervention: Concealed respiratory function monitor
Number of subjects: 35
Study: 14607447

Group type: EXPERIMENTAL
Intervention: Short-term dobutamine infusion (10 microg/kg/min) in CHF patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 48-hour dobutamine infusion (10 microg/kg/min) in CHF patients
Number of subjects: 31

Group type: COMPARATOR
Intervention: Short-term dobutamine infusion (10 microg/kg/min) in matched controls
Number of subjects: 31

Group type: COMPARATOR
Intervention: Short-term dobutamine infusion (10 microg/kg/min) in young controls
Number of subjects: 31
Study: 10948076

Group type: EXPERIMENTAL
Intervention: Salt-sensitive subjects (n=33)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Salt-resistant subjects (n=34)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: CA repeat polymorphism (14 repeats)
Number of subjects: 198

Group type: COMPARATOR
Intervention: CA repeat polymorphism (23 repeats)
Number of subjects: 198
Study: 9161192

Group type: EXPERIMENTAL
Intervention: Electronic dental anaesthesia (EDA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo-EDA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral injection
Number of subjects: 30
Study: 1616866

Group type: EXPERIMENTAL
Intervention: Depot LHRH analogue
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial treatment with LHRH analogue followed by deferred orchidectomy
Number of subjects: 0
Study: 3908283

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg t.i.d.) plus dipyridamole (75 mg t.i.d.)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo (two placeboes t.i.d.)
Number of subjects: 231
Study: 31503147

Group type: EXPERIMENTAL
Intervention: Incisional negative pressure wound therapy
Number of subjects: 441

Group type: COMPARATOR
Intervention: Standard surgical dressing
Number of subjects: 441
Study: 29357482

Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP) 1,000 mg/6 h for 24 h before resistance exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLA) for 24 h before resistance exercise
Number of subjects: 8
Study: 27011114

Group type: EXPERIMENTAL
Intervention: Semiquantitative QCA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Quantitative QCA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (without QCA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Semiquantitative QCA (multicenter study)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (without QCA, multicenter study)
Number of subjects: 30
Study: 25318029

Group type: EXPERIMENTAL
Intervention: 8-week MBSR intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 22075649

Group type: EXPERIMENTAL
Intervention: Integrated psychological intervention (IPI)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Supportive counselling (Control)
Number of subjects: 128
Study: 20418083

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 5992
Study: 18631114

Group type: EXPERIMENTAL
Intervention: Feedback intervention program in the intervention unit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control unit without feedback intervention
Number of subjects: 0
Study: 17994397

Group type: EXPERIMENTAL
Intervention: PEF-based self-management of asthma
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 80
Study: 14722174

Group type: EXPERIMENTAL
Intervention: Articaine 2% with epinephrine 1:200 000
Number of subjects: 58

Group type: COMPARATOR
Intervention: Lidocaine 2% with bupivacaine 0.5%
Number of subjects: 58
Study: 11041320

Group type: EXPERIMENTAL
Intervention: Hydrocortisone, 20 mg twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30